A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Apr 2018 Planned End Date changed from 31 Oct 2018 to 31 Mar 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 Jan 2019.
- 16 Apr 2018 Status changed from recruiting to active, no longer recruiting.